TOKYO, April 1 (Bernama-AsiaNet) -- Taiho Pharmaceutical Co., Ltd.
of Tokyo announced on April 1 results from its Phase III TERRA study on
its oral combination anticancer drug TAS-102 (product name in Japan and
the US LONSURF (R), nonproprietary names: trifluridine (FTD) and
tipiracil (TPI)) in Asian (China, South Korea and Thailand) patients
with refractory metastatic colorectal cancer (mCRC). The TERRA study met
its primary endpoint of demonstrating improvement in overall survival
(OS) in patients with refractory mCRC whose disease had progressed after
approved standard therapies. In this study, TAS-102 appeared to be
generally well tolerated and its toxicities were consistent with what
was previously reported.
More detailed results from this study will be presented at a future international academic conference.
http://mrem.bernama.com/viewsm.php?idm=26521
More detailed results from this study will be presented at a future international academic conference.
No comments:
Post a Comment